Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Accendra Health, Inc.NYSE: ACH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $6.47M (cash outflow) fell 74.1% year over year, behind the +291.7% change in trailing-twelve-month net income.

Context

  • Net income amounted to 3.7% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $1.24M (+101.2%) for the fiscal year ending Dec 2026, a step up from the -71.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.47M-100.7% QoQ
Last fiscal yearDec 2025
-$102.68M-71.7% YoY
LTMMar 2026
$701.07M+291.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.1%-92.3%-18.2 pp
1 year-71.7%+101.2%+172.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(102.68M) USD
Year-over-year change
+71.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +291.7% is the 2nd highest of 11, against a peer median of -27.9%.
  • Net income amounts to 25.8% of revenue for ACH, versus a peer median of 90.4%.
ACH Competitors
Net Income for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACHAccendra Health, Inc.LTM Mar 2026$701.07M USD+291.7%—25.8%
CGCCanopy Growth CorporationLTM Mar 2026CA$286.21M CAD-52.6%-50.8%91.6%
CABACabaletta Bio, Inc.LTM Mar 2026$175.43M USD+38.4%+46.9%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M USD-56.6%-10.1%281.6%
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M USD+26.6%+26.6%871.8%
OMOutset Medical, Inc.LTM Mar 2026$74.85M USD-34.2%-20.6%63.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M USD-46.5%-9.3%832.6%
CVRXCVRx, Inc.LTM Mar 2026$52.66M USD+2.2%+8.8%89.1%
HITIHigh Tide Inc.LTM Apr 2026CA$46.43M CAD+388.6%-10.1%6.9%
SGHTSight Sciences, Inc.LTM Mar 2026$37.25M USD-24.6%-23.6%46.8%
Peer median (excluding ACH) —-27.9%-10.1%90.4%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income221.59M22.39M(41.3M)(362.69M)(102.68M)
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
Deferred Income Tax(29.74M)(26.36M)(23.65M)(26.12M)(17.89M)
Stock-Based Compensation25.02M20.99M23.22M26.84M12.87M
Change in Working Capital(261.4M)89.77M522.29M(25.44M)65.21M
Accounts Receivables(2.2M)1.1M166.58M(94.55M)122.36M
Inventory(263.44M)166.56M224.34M(26.23M)(6.85M)
Accounts Payables3.55M13.65M31M65.19M6.48M
Other Working Capital692K(91.54M)100.37M30.15M(56.78M)
Other Non-Cash Items78.09M(10.45M)(27.22M)284.12M(273.83M)
Operating Cash Flow124.18M325.01M740.71M161.5M(101.79M)
Capital Expenditures(49.69M)(166.58M)(207.89M)(228.16M)(201.33M)
Acquisitions (Net)(43.37M)(1.68B)00324.26M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities39.43M46.71M53.62M94.33M11.12M
Investing Cash Flow(53.63M)(1.8B)(137.25M)(116.53M)144.42M
Debt Repayment(95.35M)1.58B(416.69M)(244.2M)203.5M
Common Stock Issued00000
Common Stock Repurchased0000(10.18M)
Dividends Paid(731K)0000
Other Financing Activities(33.4M)(85.4M)(637K)(23.41M)(5.24M)
Financing Cash Flow(129.48M)1.5B(417.33M)(267.6M)188.08M
Effect of Forex Changes(3.54M)(3.49M)613K(901K)1.9M
Net Change in Cash(62.47M)14.15M186.74M(223.54M)232.61M
Free Cash Flow74.49M158.42M532.82M(66.67M)(303.12M)

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.